
Boehringer Ingelheim and UK biotech firm Oxford BioTherapeutics (OBT) have signed a deal to discover novel antibody targets in cancer. …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

